Kepos Capital’s Kyntra Bio KYNB Stock Holding History

Kepos Capital’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-948	Closed	-$1.02M	–	220
2019 Q4	$1.02M	Buy	948 +394	+71%	+$402K	0.1%	127
2019 Q3	$512K	Buy	+554	New	+$608K	0.05%	191

Other funds holding KYNB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Kepos Capital's KYNB Position: Q1 2020 in Review

Kepos Capital sold out of Kyntra Bio (KYNB) in Q1 2020, closing a stake of 948 shares — an estimated $1.02M sold.

Kepos Capital first reported a position in KYNB in Q3 2019 and held it in 2 quarters. The position peaked at $1.02M in Q4 2019. 187 funds tracked by Wall St. Rank hold KYNB as of Q1 2020.

Kepos Capital reported no remaining Kyntra Bio position as of Q1 2020 after selling out during the quarter.
Kepos Capital sold 948 Kyntra Bio shares in Q1 2020, an estimated $1.02M.
Kepos Capital first reported a position in Kyntra Bio in Q3 2019 and held it in 2 quarters.
Kepos Capital's Kyntra Bio position peaked at $1.02M in Q4 2019.
187 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2020.

Based on Kepos Capital's 13F filing for Q1 2020, filed 12 May 2020.